<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02425072</url>
  </required_header>
  <id_info>
    <org_study_id>14-NEURO-05-MCC</org_study_id>
    <nct_id>NCT02425072</nct_id>
  </id_info>
  <brief_title>NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer</brief_title>
  <official_title>NovoTTFTM-100A System Therapy for Refractory CNS Involved Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Villano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that the addition of NovoTTF-100A System treatment to salvage
      chemotherapy will significantly increase time to treatment failure in the brain of small cell
      lung cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Up to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment assessed by number of participants with adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>As a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Brain Metastasis</condition>
  <arm_group>
    <arm_group_label>NovoTTF-100A plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NovoTTF-100A System with Physician's Choice Chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoTTF-100A plus chemotherapy</intervention_name>
    <description>NovoTTF-100A System with Physician's Choice Chemotherapy</description>
    <arm_group_label>NovoTTF-100A plus chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed small cell lung cancer histology with CNS metastases

          -  Parenchymal disease, ten or less lesions, and supratentorial

          -  PS 70% or greater

          -  Prior CNS radiotherapy.

          -  No previous or currently active second malignancy

          -  Age &gt; 22 years.

          -  Life expectancy of ≥ 3 months.

        Exclusion Criteria:

          -  Significant liver function impairment - AST or ALT &gt; 3 times the upper limit of
             normal; Total bilirubin &gt; upper limit of normal.

          -  Significant renal impairment (serum creatinine &gt; 1.7 mg/dL).

          -  Coagulopathy (as evidenced by PT or APTT &gt;1.5 times in control patients not undergoing
             anticoagulation).Thrombocytopenia (platelet count &lt; 100 x 103/μL).

          -  Neutropenia (absolute neutrophil count &lt; 1 x 103/μL).

          -  Anemia (Hb &lt; 10 g/L).

          -  Severe acute infection. Serious non-healing wound or ulcer on scalp

          -  Significant co-morbidities within 4 weeks prior to enrollment.

          -  Implanted pacemaker, defibrillator or deep brain stimulator, or documented clinically
             significant arrhythmias.

          -  Active implanted medical device (e.g. deep brain stimulators, spinal cord stimulators,
             vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts).

          -  Skull defect (e.g. missing bone with no replacement).

          -  Shunt

          -  Bullet fragments

          -  Evidence of increased intracranial pressure (midline shift &gt; 5mm, clinically
             significant papilledema, vomiting and nausea or reduced level of consciousness).

          -  Sensitivity to conductive hydrogels.

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John L Villano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lucille P. Markey Cancer Center at University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky, Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2015</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>John Villano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Brain</keyword>
  <keyword>Lung</keyword>
  <keyword>Small-cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

